Y-Prime Technologies LLC, an eClinical products and consulting company, is expanding its suite of eClinical software solutions with Prime Publisher™, a concatenation tool designed to streamline the content review process and combines multiple data forms into a single, navigable format.
"Prime Publisher offers an integrated, component-based approach to building document content and the flexibility to combine exactly what the reviewer needs to see and comment on," explains Dan Glass, vice president of Enterprise Content Management at Y-Prime LLC. "Focusing reviewers and their feedback in large documents containing multiple pieces of information is crucial to reducing re-work and cycle times. Prime Publisher provides much of the functionality of a full-blown system, while being easier-to-use at a fraction of the cost."
Prime Publisher simplifies difficult processes such as reviewing large sections of the eCTD. For example, a Module 2 Quality Overview contains cross-references to information contained in Module 3 Drug Product and Drug Substance Manufacturing and Stability information. A typical Module 3 might contain 200 or more documents for an initial application. Prime Publisher enables an author to select the overview and the relevant Module 3 documents combining them into a single review document. It reduces time spent flipping between submission components during review and approval processes, especially where business processes and supporting technology allows the reviewer/approver to assign workflow outcomes to all documents simultaneously.
Prime Publisher also helps in preparation for Clinical Study Reports (CSR) to a global audience. The tool allows the author to prepare a modular or component-based report to accommodate regional regulatory differences of information provided.
Prime Publisher requires minimal training and integrates with industry-leading EDMS systems or fileshares. It offers the flexibility to select virtual documents and leverage an EDMS clipboard (such as inside Documentum and other Documentum based applications) and also allows multi-select to easily integrate into existing business practices.
Earlier this year, Y-Prime launched Prime IVRS and Prime eMVR products which provide high-level capabilities for bio-pharmaceuticals and CROs as well as larger sponsors who want to enhance or replace their current systems. Both Prime IVRS and Prime eMVR are designed to work out-of-the-box and seamlessly share data with existing CTMS systems as well as other eClinical applications.
All Y-Prime products are backed by 24/7 U.S. based support, project management and development capabilities.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.